Fig. 4: CDDD11-8 inhibits growth of TNBC mammary intraductal xenograft tumours.
From: Selective inhibition of CDK9 in triple negative breast cancer
a Schematic of the Mammary Intraductal (MIND) xenograft model. Mice were inoculated with TNBC cells 5 d prior to beginning therapeutic treatment with either vehicle or CDDD11-8 (150 mg/kg/day). Treatments were administered daily (arrows). b Left panel: Tumour growth curves assessed using in vivo bioluminescence of MDA-MB-453 cells expressing luciferase. Data was analysed using a two-way repeated measures ANOVA (Interaction: F = 5.098, d.f. = 5, p = 0.0005), and least squares regression (Vehicle: R2 = 0.6890, k = 0.3988; CDDD11-8: R2 = 0.6599, k = 0.3708). Right panel: Representative bioluminescent images of mice with MDA-MB-453 MIND xenograft tumours at endpoint after treatment with vehicle or CDDD11-8. c Quantification and representative immunohistochemical images of MCL1 expression in MDA-MB-453 MIND xenografts. Data was analysed using an unpaired Welch’s test (t = 4.648, d.f. = 11.42, p = 0.0006). Scale bars represent 250 µm. d End-point bodyweights of adult NSG mice used for MDA-MB-453 MIND xenograft studies (Welch’s p = 0.6784). Data are presented relative to entry body weight. e Representative H&E staining images of mouse organs after 16 days daily treatment with either a vehicle or CDDD11-8. Scale bars = 50 µm.
